Biotek-snakken — November 2023
-
-
Genovis Q3 2023: Solid growth and profitability, Xork timeline remains on track
(Redeye - RESEARCH UPDATE 2023-11-16 07:55)
-
Video: Med Novo Nordisk og Eli Lily i front er markedet for fedmebehandling boomet. Det danske selskab Pila Pharma har siden 2014 arbejdet på en ny måde at behandle fedme og diabetes på, nemlig med en tablet. Helge Larsen har besøg af stifter og adm. dir. Dorte X. Gram, som startede sin forskning inden for diabetes allerede i 1999 hos Novo Nordisk. Det var også her, grundlaget til Pila Pharmas tablet blev lagt.https://www.proinvestor.com/boards/116808
-
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?https://www.proinvestor.com/investornyt/1080992/could-investing-10000-in-crispr-therapeutics-stock-make-you-a-millionaire
-
Efter stort fald: Novos hjerte-kar-data har medvirket til comeback i flere sundhedsaktier https://www.proinvestor.com/investornyt/1081157/efter-stort-fald-novos-hjerte-kar-data-har-medvirket-til-comeback-i-flere-sundhedsaktier
-
BRIEF-Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency
14:20 Nov 20 (Reuters) - Anavex Life Sciences Corp :
ANAVEX INITIATES REGULATORY SUBMISSION OF ORAL
BLARCAMESINE FOR
ALZHEIMER’S DISEASE TO EUROPEAN MEDICINES AGENCY (EMA)Source text for Eikon:
Further company coverage:(([email protected];))
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind